Preventative Health

Help protect adult employees from HBV* infection with HEPLISAV-B  *HBV (Hepatitis B Virus)


2 doses of HEPLISAV-B administered over 1 month protected more adults across 3 pivotal clinical trials vs 3 doses of Engerix-B®1

administered over 6 months.




In trials 2 and 3, the SPRs following HEPLISAV-B were statistically significantly higher than following Engerix-B (lower bound of the 95% confidence interval of the difference in SPRs was greater than 0%)

  • Although statistical significance was met, the test for statistical significance was not prespecified in Trial 116


HEPLISAV-B consistently protected more than
90% of patients in each trial1


  • The trials compared the rates of protective immunity (antibody concentration ≥10 mIU/mL) induced by HEPLISAV-B and Engerix-B
    • Trial 1: Month 3 for HEPLISAV-B and Month 7 for Engerix-B
    • Trial 2: Month 3 for HEPLISAV-B and Month 8 for Engerix-B
    • Trial 3: Month 6 for HEPLISAV-B and Month 7 for Engerix-B


Engerix-B is a registered trademark of the GSK group of companies.